Discussing Lilly and Ventyx Biosciences' Tamuzimod in patients with moderately-to-severely active ulcerative colitis and VTX958 in moderately to severely active Crohn’s disease

Executed on:Mar 4, 2026 9:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: NYUAssistant Professor of Medicine in the Division of Gastroenterology at NYU Grossman School of Medicine & gastroenterologist at the IBD Center at NYU Langone Health.
Manages 350 unique patients with Crohn's disease annually. 
Extremely familiar with study data and was PI on trials from Vedanta and Gilead in UC.

Interview Goal

This conversation will focus on the treatment landscape and potential use of Tamuzimod and VTX958 in patients with UC and Crohn's disease

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.